Cytokinetics Announces Three Upcoming Presentations at the American Heart Association Scientific Sessions 2022

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming poster presentations at the American Heart Association Scientific Sessions 2022 taking place in Chicago, IL from November 5, 2022 - November 7, 2022. The poster presentations include an analysis of patients hospitalized for heart failure with severely reduced ejection fraction from the Get With The Guidelines®-Heart Failure Registry as well as two analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), one relating to healthcare resource use, early benefit, and cost for North American patients most likely to benefit from treatment with omecamtiv mecarbil, and one assessing sex differences in GALACTIC-HF.

Title: Clinical Profile of Patients Hospitalized for Heart Failure with Severely Reduced Ejection Fraction: From the GWTG-HF Registry
Presenter: Stephen Greene, M.D., Assistant Professor, Division of Cardiology, Advanced Heart Failure and Transplantation, Duke University Medical Center, Duke Clinical Research Institute
Date: November 5, 2022
Session Title: Heart Failure Across the Spectrum of EF
Board Number: 2195
Session Time: 3:00 PM – 4:00 PM CT
Location: Zone 2‚ Science and Technology Hall‚ Level 3

Title: Healthcare Resource Use, Early Benefit and Cost for North American Patients with HFrEF Most Likely to Benefit from Omecamtiv Mecarbil
Presenter: Nihar R. Desai, M.D., MPH, Associate Professor of Medicine, Associate Chief, Cardiovascular Medicine, Yale School of Medicine, Center for Outcomes Research and Evaluation
Date: November 7, 2022
Session Title: Heart Failure Management on Populations and Outcomes Research
Board Number: 2106
Session Time: 11:00 AM – 12:00 PM CT
Location: Zone 2‚ Science and Technology Hall‚ Level 3

Title: Sex Differences in Heart Failure with Reduced Ejection Fraction in the GALACTIC-HF Trial
Presenter: Maria Pabon Porras, M.D., Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School
Date: November 7, 2022
Session Title: Heart Failure Management on Populations and Outcomes Research
Board Number: 2103
Session Time: 11:00 AM – 12:00 PM CT
Location: Zone 2‚ Science and Technology Hall‚ Level 3

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing reldesemtiv, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our other clinical trials, statements relating to the potential benefits of omecamtiv mecarbil or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757